PSYCHEMEDICS CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PSYCHEMEDICS CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $39.70M | Mar 16, 2018 |
| FY2017 | Dec 31, 2016 | $38.98M | Mar 16, 2018 |
| FY2017 | Dec 31, 2015 | $26.98M | Mar 16, 2018 |
| FY2016 | Dec 31, 2014 | $29.21M | Mar 7, 2017 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $6.76M | Feb 27, 2015 |
| FY2014 | Sep 30, 2014 | $7.70M | Feb 27, 2015 |
| FY2014 | Jun 30, 2014 | $7.69M | Feb 27, 2015 |
| FY2014 | Mar 31, 2014 | $7.05M | Feb 27, 2015 |
| FY2014 | Dec 31, 2013 | $6.48M | Feb 27, 2015 |
| FY2014 | Sep 30, 2013 | $7.06M | Feb 27, 2015 |
| FY2014 | Jun 30, 2013 | $6.90M | Feb 27, 2015 |
| FY2014 | Mar 31, 2013 | $6.43M | Feb 27, 2015 |
| FY2013 | Dec 31, 2012 | $5.66M | Feb 28, 2014 |
| FY2013 | Sep 30, 2012 | $6.46M | Feb 28, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.10M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $8.41M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $9.29M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $10.26M | Mar 27, 2023 |
| FY2020 | Dec 31, 2020 | $1.28M | Mar 26, 2021 |
| FY2020 | Sep 30, 2020 | $1.13M | Mar 26, 2021 |
| FY2020 | Jun 30, 2020 | ($252.0K) | Mar 26, 2021 |
| FY2020 | Mar 31, 2020 | $2.73M | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | $3.49M | Mar 26, 2021 |
| FY2020 | Sep 30, 2019 | $4.38M | Mar 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.86M) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | ($4.15M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($1.08M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($665.0K) | Mar 27, 2023 |
| FY2020 | Dec 31, 2020 | ($543.0K) | Mar 26, 2021 |
| FY2020 | Sep 30, 2020 | ($1.11M) | Mar 26, 2021 |
| FY2020 | Jun 30, 2020 | ($2.05M) | Mar 26, 2021 |
| FY2020 | Mar 31, 2020 | ($159.0K) | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | ($530.0K) | Mar 26, 2021 |
| FY2020 | Sep 30, 2019 | $677.0K | Mar 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.89M) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | ($2.92M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($1.08M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $209.0K | Mar 27, 2023 |
| FY2020 | Dec 31, 2020 | ($1.11M) | Mar 26, 2021 |
| FY2020 | Sep 30, 2020 | ($1.41M) | Mar 26, 2021 |
| FY2020 | Jun 30, 2020 | ($3.31M) | Mar 26, 2021 |
| FY2020 | Mar 31, 2020 | ($242.0K) | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | ($606.0K) | Mar 26, 2021 |
| FY2020 | Sep 30, 2019 | $1.33M | Mar 26, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $749.0K | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $1.14M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.33M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.13M | Mar 27, 2023 |
| FY2022 | Dec 31, 2020 | $1.28M | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.57M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $1.55M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.36M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $1.42M | Mar 4, 2019 |
| FY2017 | Dec 31, 2015 | $1.63M | Mar 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $929.0K | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | ($1.48M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $4.89M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $414.0K | Mar 27, 2023 |
| FY2022 | Dec 31, 2020 | ($4.08M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | $4.31M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $7.93M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $9.15M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $9.27M | Mar 4, 2019 |
| FY2017 | Dec 31, 2015 | $4.58M | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $51.0K | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $157.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $187.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $182.0K | Mar 27, 2023 |
| FY2022 | Dec 31, 2020 | $991.0K | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.68M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $1.19M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.20M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $2.01M | Mar 4, 2019 |
| FY2017 | Dec 31, 2015 | $1.75M | Mar 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.32M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $12.33M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $18.73M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $21.55M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $24.00M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $27.53M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $24.97M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $26.51M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $25.03M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $22.04M | Mar 7, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.19M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $5.65M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $7.96M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $9.31M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $11.49M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $10.71M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $6.23M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $7.89M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $9.43M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $10.36M | Mar 7, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.13M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $6.67M | Mar 24, 2025 |
| FY2024 | Dec 31, 2022 | $10.77M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $12.24M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $12.51M | Mar 27, 2023 |
| FY2022 | Dec 31, 2019 | $16.82M | Mar 27, 2023 |
| FY2021 | Dec 31, 2018 | $18.75M | Mar 30, 2022 |
| FY2020 | Dec 31, 2017 | $18.62M | Mar 26, 2021 |
| FY2019 | Dec 31, 2016 | $15.61M | Feb 25, 2020 |
| FY2018 | Dec 31, 2015 | $11.67M | Mar 4, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($18.63M) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | ($16.77M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($11.82M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($9.55M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($8.61M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($3.75M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($1.33M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | ($2.11M) | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | ($4.95M) | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | ($8.30M) | Mar 7, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.42M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $1.96M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $4.75M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.99M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $2.83M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $7.28M | Mar 26, 2021 |
| FY2018 | Dec 31, 2018 | $4.07M | Mar 4, 2019 |
| FY2018 | Dec 31, 2017 | $8.17M | Mar 4, 2019 |
| FY2018 | Dec 31, 2016 | $3.94M | Mar 4, 2019 |
| FY2018 | Dec 31, 2015 | $2.69M | Mar 4, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $2.63M | Feb 25, 2020 |
| FY2018 | Dec 31, 2018 | $1.63M | Mar 4, 2019 |
| FY2017 | Dec 31, 2017 | $3.38M | Mar 16, 2018 |
| FY2016 | Dec 31, 2016 | $3.38M | Mar 7, 2017 |
| FY2015 | Dec 31, 2015 | $5.89M | Feb 26, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 26, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 26, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Mar 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 26, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 26, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Mar 26, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Mar 26, 2021 |
| FY2020 | Mar 31, 2019 | 0 | Mar 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 6.11M | Mar 24, 2025 |
| FY2024 | Dec 3, 2024 | 6.11M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | 5.81M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 5.68M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 5.59M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 5.54M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 5.52M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 5.51M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 5.49M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | 5.46M | Mar 16, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $799.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.19M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $279.0K | Mar 27, 2023 |
| FY2022 | Dec 31, 2020 | $993.0K | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | $3.97M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $3.80M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $3.29M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $3.27M | Mar 4, 2019 |
| FY2017 | Dec 31, 2015 | $3.24M | Mar 16, 2018 |